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Abstract
This document can be treated as Final Thesis Report for the project titled ”Multi-Drug Resistance
on Cancer Cell Lines”. Drug is said to be resistant on cancer site if it doesn’t bind the specified
cancer tumor target or site. Drug Resistant mutant is a major obstacle in cancer treatment and a lot
of research have been done to overcome this phenomenon with the present technology and also with
limited success. My interests lies in understanding drug resistance or more specifically multi-drug
resistance with the help of mathematical modeling through the lens of system biology. The processes
and underlying experimental research is much applied than the simple mathematics which explains
it here. You may find some experimental quotations and results which I have to believe to be true
in order to address the problem. The central theme of this project is two-fold. First, we look at
a stochastic processes describing cancer growth, mutant formation and treatment success or failure
based on whether resistant mutants are created prior-to/after treatment or based on the rate of
growth of cancer cells under simultaneous treatment with single/multiple drugs. Further refinement
in the existing model is necessary to include biological complexity and realism. So, we incorporate
cross-resistance effects of drugs which happens when multiple drugs are used for treatment. Result
shows that cross-resistant two drugs are superior than single drug in use as most of the mutation
confers resistant to that single drug in first line therapy. Adding second drug in combination with
the first drug, despite of cross-resistance effect, improves the treatment success. We will also look
into the aspects of quiescence effects and its relation to drug resistance. Finally, at the end we will
review an optimal drug dozing regimen based on continuous and pulsed dosing scheme to delay the
resistance formation to a maximum extent that arises due to single (epi)genetic alteration only. The
stochastic process described here is muti-type branching process. We will calculate the resistance
generation probability based on initial cancer tumor load and growth or death rate of cell colony. We
will also find an average population size of resistant cells over time scale and other useful parameters
defining the multi-type branching process.
In short, this report is a ”review work” on drug resistance effect and treatment strategy with a
viewpoint of adding layers of abstraction to the existing model in order to remain close to practi-
cal/realistic conditions. Two very interesting things focused my attention in this project initially.
The first being the abrupt change in treatment response when single drug therapy is replaced with
multiple drug treatment. In my view there is still no conforming answers about what combinations
of drug is optimal for personalized treatment for various cancer types. Secondly, some explanations
in the modeling takes measurements when cancer has grown to a substantial amount after the treat-
ment had began but focus less on the cumulative growth. So I think that these two topics can invoke
some interesting questions on which research can be carried out.
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Chapter 1
Introduction to Cancer and Drug
resistance
1.1 Introduction
The field of cancer research have seen a massive support from researchers and scientists from various
domain of science and technology [2]. Cancer is a disease of abnormal genes. Alteration in one
gene however, do not suffice to develop cancer but further hit of mutants, malignancy and invasion
blows up the growth [3]. Cancer grows as a result of somatic evolutionary process. The change
or alteration in normal regulation and cell-cycle advancement, division of cells and death results
in tumor formation and cancer growth. Biological process of evolution such as cell mutation and
selection can be described with the help of stochastic processes [4] and mathematical models can build
a framework to predict and explain patterns in the success and failure of anti-cancer therapy. The
molecular level of understanding of such processes can be useful in developing anti-cancer therapy. In
traditional cancer treatment approach, chemotherapy and radiation therapy have been successful in
past and is still considered as the standard treatment of cancer but, ”targeted therapy” have gained
the focus of attention in last few decades. A short history of ”targeted anticancer therapies” is cited
in [5]. The ”targeted therapy” refers to those drugs which have a dedicated mechanism and are
active on specific targeted proteins or biological pathways to alter the abnormal growth of cancerous
cells. With the ongoing development of ”targeted therapies” mathematical models can prove to
be an effective tool to explore the combinational treatment approach and can tailor an effective
personalized treatment of cancer. The biggest advantage of using targeted therapy as compared to
other means of treatment like chemotherapy and radiation therapy is the minimal side effects due to
specificity of targeted drugs. Chemotherapy or radiation therapy kills both the cancerous as well as
healthy cells leading to severe side effects but targeted drugs do not harm healthy cells and kills only
cancer cells thus, have a selective advantage over chemotherapy and radiation therapy. The first
targeted drug which was developed and was used to block the activity of BCR-ABL kinase protein
in chronic myeloid leukemia (CML) was Gleevec (imatinib) [6] followed by the development of other
small molecule inhibitors or targeted therapies [5]. The biggest limitation of these drugs arises when
the evolution of resistance takes place and tumor growth becomes uncontrolled, so, these drugs can
no longer fight against the proliferating resistance mutants. There are two general mechanism for
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resistance generation in cancer cells [7][8]. (i) Host factors such as absorption and rapid metabolism,
which forms intrinsic resistance and, (ii) Genetic alteration leading to escape of treatment. There
are other means of resistant generation, for example, MDR or multi-drug resistance [8]. In MDR,
drugs which are structurally and functionally unrelated to each other when acted upon the cancer
target becomes simultaneous resistant. Our first half of discussion will be centered around MDR in
cancer and treatment using ”targeted drugs”. We will touch upon this topic in the next few chapters
by looking through the lens of system biology and developing few tools using stochastic processes
to build the foundation of cancer growth and its dynamics including the resistance generation and
treatment effects. We will develop the framework of cancer treatment and drug resistance in context
of chronic myeloid leukemia (CML). Subsequently we will look at quiescence effects and its relation
to drug resistance. In the last chapter we will look at another process called as muti-type branching
process which define the avalanche in cancer growth. We will use the parameters to define the events
that happens in the process and design drug administration schedules optimally with the help of
toxicity constraints family in order to avoid or maximally delay the emergence of resistance. We
should keep in mind that the theoretical work that we describe here is only valuable to the field of
cancer research if models are validated by experiment, predictions are tested, and models are revised
in the light of empirical data.
1.2 What is Cancer?
The development of a healthy human requires the cooperation of more than ten million cells in the
body. This cooperation is maintained by signals and cellular checkpoints which determine whether
cells divide, die, or differentiate. Cancer is a result of the collapse of this cooperation [9] which results
in the selfish, uncontrolled growth of cells within the body and eventually leads to the death of the
organism. Cancers arise and progress by accumulating various mutations and epigenetic changes,
which gives them a selective advantage over healthy cells, and lead to growth and pathogenesis.
However, the evolution of primary cancer do not lead to the death of organism. Some Cancer cells
acquire the ability to enter the blood stream, travel to a different site, and start growing unbounded
if enough nutrient is available in vicinity. This process is referred to as metastasis. It is usually the
metastatic growth which kills the organism.
1.3 Treatments of Cancer
Cancer treatment aims at stopping the uncontrolled growth of Cancer cells. The traditional therapies
include chemotherapy and radiation therapy. The objective behind these therapy is to damage the
genomes of cells such that they halt division and/or die. Dividing cells are targeted in this approach.
However healthy dividing cells are also affected in this approach leading not only severe side effects
but, can also induce the formation of new tumors. A better solution to avoid side effects is to target
only Cancer cells and isolate healthy cells rather than targeting dividing cells in general. We call
such approach as ”targeted treatment approaches”. Targeted drugs or small molecule inhibitors
specifically target molecular defects in Cancer cells which eliminates their ability to grow out of
control. The success behind these targeted drugs lies in halting the mechanism of growth and
reducing the tumor load. The treatment of chronic myeloid leukemia (CML) with the targeted
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inhibitor imatinib and subsequent inhibitors distinib and nilotinib has seen the greatest success so
far [10]. Presently in many cancer types the defects that drive and maintain aberrant proliferation of
cancer cells remain poorly defined, thus preventing the development of targeted inhibitors. However,
new targeted drugs are in clinical trials and the scope of research on these classes of drugs has a well
promising future.
1.4 Small Molecule Inhibitors
Small Molecule Inhibitors or ”Targeteted therapies” are used for targeted treatment of cancer. These
inhibitors counters specific cellular defects and resists the growth of cancer. Targeted therapies shows
high effectiveness and a high specificity for cancer cells as compared to chemotherapy and radiation
therapy. These drugs binds specific tumor targets and cures the tumor load. However drug resistance
is a major problems in targeted treatment approach especially in the advanced phase of the disease,
and can lead to treatment failure. The inhibitors which we will be focusing on in our cancer modeling
exercise are imatinib, disatinib and nilotinib. We will discuss everything here in context of chronic
myeloid leukemia (CML).
1.5 The Role of Mathematical Models
In addition to clinical and experimental research, the field of mathematical oncology, which uses
mathematical and computational models can be very useful to study the treatment of CML with
small molecule inhibitors. The concept of evolution plays a special role in this context. Mathematical
models allow us to investigate the evolutionary dynamics of drug-resistance in cancer, which in turn
can lead to the design of combinational drug treatment strategies aimed at overcoming treatment
failure due to resistance. Moreover mathematical models provide insight and make predictions that
would be impossible to achieve by experimental and clinical study alone. The biggest challenge
faced by modelers is that the complexity of the process underlying tumor growth, progression, and
therapy is the enormous, and excluding it makes the model very simplistic, which in turn increases
uncertainty that arises when formulating biological processes in terms of mathematical models. We
will start with a simple definition of biological processes underlying cancer growth and mutant
generation and keep on refining the model by adding the complexity of the process and explaining
it using mathematical equations.
1.6 Scope of the text
The contents presented in the subsequent chapters is a review work in order to understand the
underlying principles of emergence of drug resistance in cancer and its treatment using multiple
drugs. One reason for cancer generation is the development of multiple point mutations, others
include gene amplification, chromosomal instability etc. We will focus on the former case in context
of CML. It is widely accepted that first line imatinib therapy fails in many CML patients and calls
for second generation inhibitors such as disatinib and nilotinib. We are interested to understand that
how a combination of these three inhibitors are useful in the treatment of CML. In chapter 2 we will
use some mathematical tools to model the growth of cancer, the generation of resistance, and the
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effect of multidrug treatment. The methodology is stochastic, based on the description of a cellular
colony as a birth–death process with mutations. We will analyze a simple model by assuming that
there is no cross-resistance effects of these three drugs. In chapter 3 we will include cross-resistance
effect to modify and extend the model developed in chapter 2 whereas, In chapter 4 we will focus
on the effect of Cellular Quiescence on the evolution of drug resistance in CML. In the last chapter
we will look at another process called as muti-type branching process which define the avalanche
in cancer growth. We will use the parameters to define the events that happens in the process and
design drug administration schedules optimally with the help of toxicity constraints family in order
to avoid or maximally delay the emergence of resistance. It is very important to keep in mind that
the experimental setups and results presented here is quoted with appropriate reference and this is
something which is taken for granted in order to address the problem.
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Chapter 2
Evolution of Resistance and Multi
Drug treatment
2.1 Introduction
The mathematical framework of drug resistance was first elucidated by J.H. Goldie and A.J. Coldman
who pioneered the field of mathematical modeling of drug resistance using stochastic processes.
Their ground breaking work can be seen here [11]. The framework presented in this chapter follows
the tradition of [11] and extends the work further. This chapter focuses on developing a stochastic
framework of a process called ”Death and Birth Process in a cellular colony” to address the treatment
outcome using multiple drugs [10]. We will develop a combinatorial mutation network to analyze
how drugs in combination becomes resistant simultaneously. We will frame the process dynamics
and include drug induced effects on the proliferating cell population. Every events that goes into
the process has certain probabilities of occurrence and we will accumulate all these probability to
explain the events mathematically. Kolmogorov equation is useful to analyze the process in general
but we will use it in the special case only, ie., for the case of one and two drug cases. Successful
treatment guarantees complete extinction of cancer cells and we will show that it happens only when
the probability of non-production of resistant mutant equals the probabilities of extinction. The
analysis is taken in the simplistic case by considering symmetric relations in parameter assumptions.
Birth and Death rates (L,D) of cancerous cells are two entities which gives a rough idea about the
overall growth rate of cancer. This quantity is related through a term called turnover rate (D/L).
We will see that the dependence of turnover rate on successful treatment vanishes when single drug
is used whereas, there will be a severe dependence of (D/L) on treatment outcome as the number of
drugs are increased. At the end we will frame an equation for threshold tumor size and say that if
this limit or some fraction of it exceeds, it is very difficult to prevent the emergence of resistance and
a person may die. Under such assumption we can fix few parameters for example, like observable
mutation rates ”u” and fix the number of drugs useful for successful treatment. The same goes when
we fix other parameters like death rate of cells etc.
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2.2 Model: Birth-Death Process and Mutant generation
There are two kinds of cells in a cell colony namely, sensitive cells upon which the drug that we
use is effective and, the resistant/mutant cells which are inactive to respond to any drug. We will
assume that the only events that goes in the cellular colony to form cancer tumor are the following,
also refer figure 2.1.
• Faithful reproduction: Increases the number of cells by one.
• Death: Reduces the number of cells by one.
• Reproduction with a mutation: Increases mutant type cell by one.
• Transformation: Decrease sensitive cells and, simultaneously increase mutant cell.
Figure 2.1: Birth & Death Process along with Mutations in a cell colony. [10]
The population of the cell colony becomes heterogeneous when cell mutates and give rise to a different
kind of cell or mutant cell. The cells colony comprises of various ”cell type” namely a combination
of sensitive cells and resistant/mutant cells. When a drug is administered then sensitive cells dies
while resistant cell remains intact. So, a cell can have two possible states namely resistant state or
susceptible state. Let us say that the number of sensitive and resistant cells are denoted by integers
i and j respectively. lets say that vectors (i, j) forms a state space. Sensitive cell mutates with rate
u, looses its property and gains a resistance property. We show this change in property through a
combinatorial mutation diagram as X0
u−−→ X1. In the notation Xk the subscript k differentiates
between cell types. Let us say that k = 0 represents susceptible property of the drug, and k = 1
represents resistant property of the drug. If we extend the same formulation for the case of two
drugs in use then the network will look look a square with arrows coming out from any of the one
node and resting on the diagonal node. If we incorporate one more drug then the combinatorial
mutation network for the case of three drugs looks like the one as shown in figure 2.2 [12, 13]. Each
mutation rates u1, u2, u3 are taken different in general. If we look at the diagram and for example we
see that state ”000” is fully susceptible and state ”111” has become fully resistant while mutating
through various path with different mutation rates and resting to fully resistant state. There can
be multiple pathways for a cell to get converted from fully susceptible to complete resistant state.
Note that the state has three positions corresponding to drug number. Similarly we can extend the
same network to accommodate more number of drugs and analyze the model. In the next section
we will represent the model in general but analyze it in special case of two drugs only in order to
understand the methodology in simple form.
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Figure 2.2: Combinatorial Mutation Network for three drugs in use. [10]
2.3 Process Dynamics and Modeling
The dynamics of the model is a Markov birth–death process, continuous in time and have discrete
state-space as (i, j). Four events namely (faithful division, death, mutation, and transformation)
occurs in the cell colony and their probability of occurrence is proportional to the infinitesimal time
increment, ∆t in which either of one of the four events occurs one at a time. Each event may change
the resistance phenotype. For example, in figure 2.2 for m = 3 drugs in use there are eight different
resistant phenotype given by (000, 001 ..... 111). As said the time of occurrence of one event at
a time ∆t is very small, the probability associated with each of the four events where resistance
phenotypes changes from one type to another through (faithful division, death, mutation, and trans-
formation) is given below. Figure 2.3 shows an example of node ”As” in a mutation network where
0 ≤ s ≤ 2m−1, us,in1,2 is the rate of mutation rate needed to produce resistance phenotype ”As”
whereas, us,out1,2,3,4 defines the mutation rate needed to produce other different resistance phenotypes.
Consider the following events with associated probabilities,
• Faithful division: The probability associated with identical creation of a cell of type ”As”
is Ls(1−
∑
j u
s,out
j )∆t.
• Mutation: The probability that a cell type ”As” mutates to produce another cell type
”As,nxtj ”; ∀ j, is Lsus,outj .
• Cell Death: With probability associated with cell death is ds∆t.
• Cell Transformation: The probability that a cell type ”As” transforms to another cell type
”As,nxtj ”; ∀ j, is Ksαs,outj . In our exercise we will consider no transformation, or Ks = 0.
NOTE: The quantity Ls is the birth rate, and ds = Ds +Hs is the death rate of type s. Ds is the
natural death rate and Hs is the drug induces death rate of various cell type. The growth of wild
type cells are generally greater than its natural death rate (L0 > D0) or 0 ≤ D0/L0 < 1. The term
D0/L0 is the turnover rate of wild type cells and it points the slow-growth or high-growth cancer.
On the application of drug the cell colony decreases in size due to the high death rate of wild type
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cells only. The quantity Hs is associated with drug induced death rate. If any cell responds to Hs
then we assume Hs = H = constant.
Figure 2.3: An example of a vortex in a mutation diagram
2.3.1 Process Analysis with one drug only
The stochastic process analysis done here is applicable for one drug treatment only. In further
section extension is made to accommodate multiple drugs in general. System state integer vectors
(i0, i1) comprises of sensitive cells and resistant cells respectively. The probability of these two cell
type to be in state (i0,i1) at time t is given by the quantity ϕi0,i1(t). According to Kolmogorov
forward equation ϕi0,i1(t) is given by,
ϕi0,i1 =
[
L0(1− u)(i0 − 1)ϕi0−1,i1 + L1(i1 − 1)ϕi0,i1−1
]
+
[
L0ui0ϕi0,i1−1
]
+
[
d0(i0 + 1)ϕi0+1,i1 + d1(i1 + 1)ϕi0,i1+1
]
−
[
ϕi0,j0(L0 + L1 + d0 + d1)
]
(2.1)
The term in the first square bracket represent faithful division of cells, followed by division with
mutation in the second bracket. The term in the third bracket is for death of cells and lastly a
negative term represents no change in the system state. We introduce a new quantity here called as
probability generating function given by,
Ψ(ξ0, ξ1; t) =
∑
i,j ϕi0,i1ξ
io
0 ξ
i1
1 (2.2)
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Solving equation 2.1 and 2.2 we can obtain a closed form PDE given by,
∂Ψ
∂t
=
∂Ψ
∂ξ0
(
L0(1− u)ξ20 + d0 − ξ0(L0 + d0 − L0uξ1)
)
+
∂Ψ
∂ξ1
(
L1ξ
2
1 + d1 − ξ1(L1 + d1)
)
(2.3)
The solution of the above partial differential equation (PDE) can invoke many interesting questions.
We will use this PDE to address the problem of success or failure of therapy.
2.3.2 Process Analysis with multiple Drug
In this subsection a similar analysis as seen previously can be done to incorporate multiple drugs.
In general consider that we use m number of drugs. The probability mass function is written as
ϕi0,...,in(t). Similarly, the probability generating function be given by,
Ψ(ξ0, ..., ξn; t) =
∑
i0,..,in
ϕi0,..,in(t)
n∏
s=0
ξiss (2.4)
If we solve equation 2.4 using probability mass function ϕi0,...,in(t) then we will obtain a hyperbolic
partial differential equation as,
∂Ψ
∂t
=
∑
s
∂Ψ
∂ξs
[
ξ2sLs(1− us,out) + ds + ξsLs
∑
j
ξju
s,out
j +Ks
∑
j
ξjα
s,out
j − ξs(Ls + ds −Ksαs,out)
]
(2.5)
where the notation us,out and αs,out is given as,
us,out =
∑
j
us,outj α
s,out =
∑
j
αs,outj
2.3.3 Solution of system of PDE and HPDE
Till now we have obtained a closed form solution of kolmogorov forward equation for single drug
treatment as well as multiple drug treatment. We need the closed form of equation 2.3 and 2.5
to address the problem of treatment success or failure. We can solve the system of PDE with the
help of standard method of characteristic [10]. The characteristics equation obtained after solving
equation 2.5 is given by,
ξ˙s = Ls(1− us,out)ξ2s +
[
Ls
∑
j ξju
s,out
j − (Ls + ds +Ksαs,out)
]
ξs −Ks
∑
j ξjα
s,out
j + ds (2.6)
If M0 cells are not resistant any drugs at t = 0 then ξM0,0,...,0(0) = 1 and,
Ψ(ξ0, ..., ξn; 0) = ξn(0)
M0
Ψ(ξ¯0, ..., ξ¯n; t¯) = ξn(t¯)
M0 and t = t¯ > 0
Consider the simplest two stage treatment process:
• 0 <t <t∗ : Pretreatment phase, No drugs in use such that Hs = 0, ds = Ds.
• t ≥ t∗ : Treatment phase, Includes drug induced death of cells such that ds = Ds +Hs.
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Size of tumor at the start of treatment, ie., at t = t∗ can be written as,
N = M0 exp
(
(L0 −D0)t∗
)
(2.7)
We are interested to calculate the function Ψ(ξ¯0, ..., ξ¯n; t∗+ t¯), where t¯ ≥ 0 to obtain the information
at time ahead of the start of treatment. The intuitive idea for solving this problem is as follows:
• We know the initial conditions namely ξ0(0) = ξ¯0, ..., ξ¯n(0) = ξ¯n apriori. We need to solve
the equation 2.6 using treatment coefficients and the initial conditions. The solution obtained
would be ξ0(t¯), ..., ξn(t¯).
• Next, ξ0(t¯), ..., ξn(t¯). becomes the initial condition. Use pretreatment coefficients to obtain the
solution ξ0(t∗), ..., ξn(t∗) at time t = t∗ which is Ψ(ξ¯0, ..., ξ¯n; t∗) = ξn(t∗)M0
2.3.4 Treatment Success Vs. Treatment Failure
An intuitive idea says that if the fully resistant mutant are never produced in the process then there
is a fair chance that the cell colony gets extinct as a result of multiple drugs in use. We formulate
the idea into the mathematics with following few notations,
• Ψ(0, 1, ..., 1; t): Probability of non-production of fully resistant mutant or cell type ”An” at
time t under the initial conditions ξ0 = 0 , ξi = 1 ; 1 ≤ i ≤ n.
• Ψ(0, 0, ..., 0; t): Probability that all cells (sensitive/resistant) of all type have got extinct under
the initial conditions ξ0(0) = ξ1(0) = .... = ξn(0) = 0.
If we put the arguments of Ψ(0, 1, ..., 1; t) and Ψ(0, 0, ..., 0; t) in equation 2.4 and if the condition in
equation 2.6 is satisfied then under the above initial condition as time t→∞ we get,
Pnonprod(t) = Ψ(0, 1, ..., 1; t) = ξ0(t)
M0
Pext(t) = Ψ(0, 0, ..., 0; t) = ξ0(t)
M0
limt→∞ Pext = limt→∞ Pnonprod
The probability of treatment failure can be defined as,
Pfailure(t) = 1− Pext = 1− Pnonprod = 1− ξM00 (2.8)
The successful extinction of cell colony can be achieved if it get extinct spontaneously or when
tumor grows but treated successfully by the therapy. The former being the transient solution for
the quantity Ψ(0, 0, ..., 0; t) and the later reflects the steady state behavior as shown below.
Ψ0,0,...,0(t) = Ψ(0, 0, ..., 0; t) = ξ0(t)
M0 = (D0/L0)
M0 + (1− (D0/L0)M0)Psuccess(t)
Psuccess(t) =
ξ0(t)
M0−(D0/L0)M0
(1−(D0/L0)M0 ) (2.9)
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2.4 Simplifying calculations using symmetrical coefficients
If we look again at the figure 2.2, we can see a vertical strip of classes of phenotype which are either
fully susceptible to drug, resistant to a single, multiple or all drugs. If we can group such resistant
types into classes such that in each class the cell types are resistant to k drugs and susceptible to
(m− k) drugs. The number of such classes are k, and 0 ≤ k ≤ m. Also, ξs reduces to ξk only with
0 ≤ k ≤ m. If we further let the birth and death rates in each class to be equal, along with all
mutation rates equal we can make further simplification. In this way we achieve dimension reduction
from n = 2m + 1 to m+ 1 and equation 2.6 reduces to a simplified form as,
ξ˙k = Lk(1− (m− k)u)ξ2k +
[
(m− k)Lkuξk+1 − (Lk + dk)
]
ξk + dk 0 ≤ k ≤ m (2.10)
2.4.1 Process Analysis with two drugs
A boolean combination of two different drug type produces four phenotypes of resistance; as com-
pared to eight phenotypes in case of three drugs as shown in figure 2.2. For two drugs (m=2) the
four phenotypes are ”A00”, ”A01”,”A10”, ”A11”. As we observed the case of one drug in section
2.2 we can similarly extend the same idea to accommodate two drugs. The function ˙ϕi00,i10,i01,i11
satisfies the following Kolmogorov forward equation.
˙ϕi00,i10,i01,i11 =[
L00(1− u1 − u2 − u12)(i00 − 1)ϕi00−1,i10,i01,i11 + L10(1− u2 − u12)(i10 − 1)ϕi00,i10−1,i01,i11
+ L01(1− u1 − u12)(i01 − 1)ϕi00,i10,i01−1,i11 + L11(i11 − 1)ϕi00,i10,i01,i11−1
]
+
[
i00
(
u1ϕi00,i10−1,i01,i11 + u2ϕi00,i10,i01−1,i11 + u12ϕi00,i10,i01,i11−1
)
+ i10
(
u2ϕi00,i10,i01,i11−1 + u12ϕi00,i10,i01,i11−1
)
+ i01
(
u1ϕi00,i10,i01,i11−1 + u12ϕi00,i10,i01,i11−1
)]
+
[
d00ϕi00,i10+1,i01,i11 + d10ϕi00,i10+1,i01,i11 + d01ϕi00,i10,i01+1,i11 + d11ϕi00,i10,i01,i11+1
]
−
[(
i00(L00 + d00) + i10(L10 + d10) + i01(L01 + d01) + i11(L11 + d11)
)
ϕi00,i10,i01,i11
]
(2.11)
2.4.2 Equations for the Characteristics
If we look at earlier formula of probability generating function and we substitute m = 2 to consider
only two drugs then the probability generating function is given by,
Ψ(ξ00, ξ10, ξ01, ξ11; t) =
n∑
0
ϕi00,i10,i01,i11(t)ξ
i00
00 , ξ
i10
10 , ξ
i01
01 , ξ
i11
11 (2.12)
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By solving equation 2.11 and 2.12 we obtain the equation of characteristics as,
˙ξ11 =
[
L11ξ
2
11 − (L11 + d11)ξ11 + d11
]
˙ξ10 =
[
L10ξ
2
10(1− u2)−
[
(L10u2ξ10 − (L10 + d10)
]
ξ10 + d10
]
˙ξ01 =
[
L01ξ
2
01(1− u1)−
[
(L10u1ξ01 − (L01 + d01)
]
ξ01 + d01
]
˙ξ00 =
[
L00ξ
2
00(1− u1 − u2)−
[
(L00(u1ξ10 + u2ξ01)− (L00 + d00)
]
ξ00 + d00
]
(2.13)
Under appropriate initial conditions, we can solve the systems of equations in 2.13 to calculate the
probability of treatment success recursively. We will look into the solution later in the section.
2.4.3 Statistical count of cells in various classes
If one wishes to calculate the Mean numbers of cells in each class as grouped using symmetric
coefficient constraints (Section 2.4) then we can obtain all the moments as shown below,
x00(t) =
∑
i00ϕi00,i10,i01,i11(t) x10(t) =
∑
i10ϕi00,i10,i01,i11(t)
x01(t) =
∑
i01ϕi00,i10,i01,i11(t) x11(t) =
∑
i11ϕi00,i10,i01,i11(t)
where the summation is performed over all the four indices’s. We obtain,
˙x00 =
[
L00(1− u1 − u2)− d00
]
x00
˙x10 =
[
L10(1− u2)− d10
]
x10 + L00u1x00,
˙x01 =
[
L01(1− u1)− d01
]
x01 + L00u2x00,
˙x11 =
[
L11 − d11
]
x11 + L10u2x10 + L01u1x01.
(2.14)
Under the initial conditions: x00(0) = M0 x10(0) = x01(0) = x11(0) = 0. we can obtain the
Mean numbers of cells in each class by solving the above state space equation.
2.5 Resistant Mutant comes in picture again
Resistance mutant if happens to be present forms a major obstacle in treatment. Drugs used in
treatment fails and there is nothing that we can do. We have to know that is it before the treatment
that it formed or during the process of treatment? Again to make life simple we will use only
symmetric coefficients described in section 2.4. Consider two new notations,
• P ↑(N) : Probability to develop resistance as t→∞, if mutation happens iff before treatment.
• P ↓(N) : Probability that at least one fully resistant mutant exist as t→∞ and no mutation
happens after treatment begins. Colony size is N in both cases.
.
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2.5.1 Presence of resistant mutants before treatment phase only
If resistant mutant exists before therapy begins then let us consider that no mutants are generated
during therapy. Do the colony ever vanishes as t → ∞ or in other words what is the probability of
non-extinction of colony?
• Characteristic equation for system before treatment
ξ˙i = L(1− i u)ξ2i +
[
i L u ξi+1 − (L+D)
]
ξi +D
˙ξm = Lξ
2
m − (L+D)ξm +D
(2.15)
• Characteristic equation for system as and after treatment starts
ξ˙i = L(1− i u)ξ2i +
[
L+D +H
]
ξi +D +H
˙ξm = Lξ
2
m − (L+D)ξm +D
(2.16)
As explained in section 2.3.3 we can solve the above two set of system of equation by first obtaining
the steady state variable of system of equation 2.16 and then substituting the value as an initial
condition in system of equation 2.15. Preexistence of resistant mutants thus obtained is,
P ↑(N) = limt→∞Ψ(0, 1, ..., 1, t0 + t¯) = 1− ξ0(t∗)M0 ; t∗ = 1L−D ln(N/M0) (2.17)
2.5.2 Mutants generation during treatment phase only
We assume that there is no mutant cell initially and is grown during treatment phase only. The
colony comprises of N susceptible cells with no resistant cells. In this case we assume that no
mutants are present beforehand and are only generated after the start of therapy. The Systems of
equation for this case is,
ξ˙i = L(1− i u)ξ2i +
[
i L u ξi+1 − (L+D +H)
]
ξi +D +H 0 ≤ i ≤ m.
˙ξm = Lξ
2
m − (L+D)ξm +D
ξi(0) = 0 0 ≤ i ≤ m.
(2.18)
We solve the system of equation similarly under the limiting case u (L−D) and t→∞ then,
lim
t→∞ ξi =
i!(L−D)Li−1ui
(D +H − L)i 0 ≤ i < m.
lim
t→∞ ξm =
D
L
(2.19)
The probability to develop resistance as t −→∞ is given by,
P ↓(N) = 1− lim
t→∞ ξ0(t)
N
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Suppose that the number of drugs used is m then from equation 2.19 we get
P ↓(N) = 1−
[
1− m!(L−D)Lm−1um(D+H−L)m
]N
(2.20)
Observation: Compare Equation 2.17 and Equation 2.20
• If tumor size N is large probability of success is low.
• If P ↑(N) > P ↓(N), Fully resistant mutants are created before therapy and treatment phase is
less useful.
• If P ↑(N) < P ↓(N), Most mutants are generated after treatment starts.
2.5.3 Special case: One Drug
Generation of mutants during treatment: If one drug (m = 1) is used for treatment then the
probability to create resistance during therapy (Equation 2.20) is,
P ↓(N) = 1−
[
1− (L−D)u(H−(L−D))
]N
(2.21)
Under a certain threshold value of drug induced death rate H as H = Hc = 2(L − D) ”which we
can set by using appropriate drug concentration” we get,
P ↓(N) = 1− (1− u)N ≈ 1− exp(−Nu) ≈ Nu (2.22)
Generation of mutants before treatment: If we set m=1 and solve equation 2.15 then we will
end up getting the following result. Note that we are looking for a mutant to be created and survived
in order to detect it at diagnosis.
ξ0(t) = 1− (exp[(L−D)t]− 1)Lu
L−D ≈ 1−
NLu
M0(L−D) (2.23)
The probability of mutant creation from the susceptible cell when the colony size reaches N is,
Pcreate = 1− ξM00 ≈
NLu
(L−D)
The probability for survival of at-least one mutant cell as t→∞
Psurvive = 1− D
L
Pfailure = P
↑(N) = PcreatePsurvive = Nu (2.24)
Conclusion: One Drug
• The probability of failure is dependent on colony size N and u and depends on the presence
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of resistant mutant before the treatment. Mutant generation before and after treatment is
independent of turnover rate of cancer.
• If H = Hc = 2(L−D) then P ↑(N) = P ↓(N)
• For the realistic case ie., If H > Hc = 2(L−D) then P ↑(N) > P ↓(N), or resistance is mostly
generated before the start of therapy.
2.5.4 Special case: Two Drug
Generation of mutants during treatment: If two drugs (m = 2) are used for treatment then
the probability to create resistance during therapy is given as,
P ↓(N) = 1−
[
1− 2(L−D)u2(H−(L−D))2
]N
(2.25)
P ↓(N) =
[
2(L−D)u2N
(H−(L−D))2
]
; Nu2  1 (2.26)
Generation of mutants before treatment: In case of two drugs (m=2) ”we will make the
approximation of a doubly stochastic process, whereby generation of each one-hit mutant leads to a
birth–death process, all of which are independent and identically distributed” [10]. The probability
of mutant creation and survival is,
Pcreate = 2
(
Lu
L−D
)2
N
(
ln
N
M0
− 1
)
and Psurvive = 1− D
L
P ↑(N) = PcreatePsurvive = 2Lu
2N
L−D
(
ln NM0 − 1
)
(2.27)
We see that if the number of drugs is increased the term L and D appears which defines the turnover
rate of cancer. P ↑(N) now depends on the turnover rate, D/L. From equation 2.27 we can observe
that if the natural death rate of tumor cells D is high then resistant mutants are produced at a
higher rate and treatment fails. See Figure 2.4. Also if D → L then there is no solution. This is an
inherent problem with this analysis. Taking the ratio of equation 2.26 and 2.27 for M0 = 1 we get,
P ↓
P ↑
=
[
H
(L−D) − 1
]−2[
ln(N)− 1
]−1
P ↓
P ↑
< 1 ⇐⇒ H > (L−D)(1 + (ln(N)− 1)−0.5)
Conclusion : Two Drugs
• For two drugs, the generation of resistant mutants in the pre-treatment phase depends on the
turnover rate, D/L.
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Figure 2.4: Generation of mutant before treatment, Tumor size vs. death rate (D) of tumor [10].
2.6 Quantifying Treatment Success
Probability of successful treatment: Probability of treatment success [10] can be written as,
Psuccess(N) ≈
(
1− HNu(H+D−L)M0
)M0
(2.28)
If therapy is very strong such that H  L−D, then probability of successful therapy is independent
of turnover rate D/L of cancer,
Psuccess(N) ≈
(
1− NM0u
)M0
(2.29)
2.7 Summary
In this chapter formulation and analysis of a stochastic model of death-birth process with mutation
under multi-drug treatment was carried out to investigate the dependence of treatment outcomes
on the initial tumor load (N), mutation rate (u) and the turnover rate (D/L) of cancerous cells.
We saw the importance of pretreatment phase in successful treatment of cancer and related mutant
production. Two special cases namely the use of one/two drug apart from general case is set as an
example to demonstrate the process underlying growth of cancer.
We observed that in case of one drug:
• The probability of failure in the treatment of a given cancer size (N) is independent of turnover
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rate (D/L) of cancer,
• If H = Hc = 2(L−D) then P ↑(N) = P ↓(N)
• For the realistic case ie., If H > Hc = 2(L−D) then P ↑(N) > P ↓(N), or resistance is mostly
generated before the start of therapy.
In case of two or more drug:
• Pre-treatment phase plays the dominant role in treatment failure and; generation of resistance
in treatment phase is less important,
• High-turnover cancers have a higher probability of treatment failure (for the same size N) than
low-turnover cancers;
• Both of these effects become stronger for larger numbers of drugs.
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Chapter 3
Re-Modeling and Cross Resistance
of Drugs
3.1 Goal
The first half of this chapter has the following goal: To understand the reason for the
difference between the single drug treatment and multi-drug treatment cases as observed on the
basis of turnover rate dependence. The paper [14] is based on deterministic framework in contrast
to the earlier work which were stochastic to mainly address the problem of parameter dependence
of success under single drug treatment.
The second half of the chapter has the following goal: To study the optimum use of cross-
resistant drugs instead of non-cross resistant drugs when mutation (here T315 mutation) confers
complete resistance to a number of drugs (here drugs in use are imatinib, disatinib and nilotinib) in
the treatment of chronic myeloid leukemia (CML).
3.2 Introduction
Earlier work on the process modeling can be explained alternatively in a deterministic framework as
well. In this section we will formulate a deterministic model of the process where two cell types grow,
die and mutates as seen earlier. We will focuses our attention to address the problem of dependence
of treatment success/failure on turnover rate (D/L) of the cancer under the use of single drug. The
result says that the treatment success always depends on the turnover rate of cancer.
3.2.1 One drug treatment: An Elementary Model
Let us assume that the population comprises of two kinds of cells namely, Wild-type cancer cells
denoted by N(t) and Resistant cells denoted by R(t) at some point in time. We will consider two
phases namely pre-treatment and treatment phase. Other symbols have their usual meaning.
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Pretreatment phase, t ≤ t∗
N
′
(t) = (L−D)N(t)
R
′
(t) = (L−D)R(t) + uN(t)
N(0) 6= 0, R(0) = 0
(3.1)
Treatment phase, t ≥ t∗
N
′
(t) = (L−D −H)N(t)
R
′
(t) = (L−D)R(t) + uN(t)
N(t∗), R(t∗)
(3.2)
t∗ =
1
L−Dln
(
N(t∗)
N(0)
)
(3.3)
Solving equation 3.1 using equation 3.2 and related treatment phase conditions we get the total
amount of resistant cells at the time of diagnosis which is,
R(t∗) = N(0)ut∗exp
[
(L−D)t∗
] ≈ N(t∗) u ln[N(t∗)/N(0)]
L
[
1−(D/L)
] (3.4)
3.2.2 Observations
• The amount of resistant mutants generated before the beginning of the treatment clearly
depends on the turnover rate.
• The slower the growth of the cancer (i.e., D/L ≈ 1) the larger is the larger is the number of
resistant mutant.
• Conversely, faster the tumor grows (i.e., D/L ≈ 0) smaller is the resistance generation prior
to treatment. See equation 3.4.
3.2.3 Resistance progeny
Now, assume that as soon as therapy begins at t = t∗ no mutants are allowed to be created. So, the
only resistance that remains are the one created beforehand and we call it as ”resistance progeny”
and denote it by Rp(t). Rp(t) is given by
Rp(t) ≈ M0 u ln(M0/N0)
L
[
1− (D/L)] exp[(L−D)t] (3.5)
The additional term exp
[
(L − D)t] accounts for the growth of the resistance progeny during
treatment. Similarly such dependence can be shown to be present also in the case of a multi-drug
therapy.
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3.2.4 Conclusion and Discussion
• If we look at the equation 3.5 then we will see that the resistance progeny vanishes only when
t → ∞. So it is only at t = ∞ the result shows a lack dependence of the resistance on the
turnover rate.
• The analysis done above is deterministic in nature and is based on an elementary compart-
mental system of linear ordinary differential equations, rather than on stochastic processes as
seen in previous chapter.
• Irrespective of the number of drugs used the a related quantity Rp(t) shows that treatment
outcome always depends on the turnover rate D/L of cancer.
3.3 Cross Resistance of drugs: In-Vitro Experiment
Our earlier understanding of the process was based on the assumption that no cross resistance is
observed in drugs. But, now we will dig deeper to understand the phenomenon of cross resistance
of drug and its implications. when resistance against one drug implies resistance to other drugs
in use than we encounter cross resistance effect. To uncover the principles of drug resistance in
cancer, ”drugs in different combinations and different concentrations have been used in In-Vitro
experiment”. Now I quote the following from [10].
In papers [15],[16] a quantitative analysis of mutations has been performed. In In-Vitro experiments
described in these papers, CML cancer cells, Ba/F3, p210bcr−able were exposed to a minimally cytotoxic
agent, N-ethyl-N-nitrogenous (ENU), a potent inducer of point mutations. The cells were then cultured
in 96-well plates supplemented with graded concentrations of inhibitors. After some time (about 28
days), wells with positive outgrowth were expanded and then sequenced for mutations. Three different
inhibitors namely imatinib, dasatinib, and nilotinib, were used, in different combinations and solo. In-
hibitor concentrations used for the three inhibitors are listed in Table 3.1. The noted concentrations were
motivated by the fact that nilotinib is at least 20-fold and dasatinib at least 300-fold more potent than
imatinib [15]. After analysis of the total of 768 wells, there were 726 mutations. Of the 30 specific point
mutations that had been previously identified in imatinib resistant patients, 25 were recovered in this
experiment. In total, 26 point mutations were identified.
In vitro experiments suggest that,
1 Different resistant mutant types are produced when concentrations of drugs are used alters.
2 Mutants are resistant to more than one drug and shows cross resistance effects.
Low Dose (nM) Medium Dose (nM) High Dose (nM)
Imatinib 2000 4000-8000 16000
Dasatinib 5 10-25 100-500
Nilotinib 50-250 500-1000 2000-50000
Table 3.1: Categorization of the doses of each inhibitor, as used in [16]
The summary of the experiment is shown in figure 3.1(a)-(b). In particular we can see there is
only one mutation that confers resistance to all the three drugs. This mutation is termed as T315
mutation which shows resistance to all the three drugs used.
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3.4 Methodology
We incorporate cross-resistance effects of drugs under multi-drug treatment as shown in figure 3.2(b).
The same combinatorial mutation network under no cross resistance as analyzed in in chapter 2 is
also shown to the left in the figure 3.2(a). Let ui,j be the mutation rate, which is nothing but
weighted mutation rate ki,ju. The subscript i, j, k are the three drugs in used and the term u is
the basic mutation rate. For two drugs, there are three such rates, u1,2, u1,3, u2,3. For three drugs
k1,2,3 = 1 when all three drugs are given in high concentration, refer figure 3.1(a)-(b). We just need
to add the weighting factor ki,j,k to our previous model to include cross-resistance effect in our new
model. The factor ki,j,k are the integers represented in the boxes in figure 3.1.
Figure 3.1: (a) Number of doubly resistant mutants for different combinations of drug doses. (b) Number
of triply resistant mutants [15].
Figure 3.2: (a) Combinatorial mutation diagram for different resistance classes under no cross-resistance.
(b) Under cross-resistance drugs. Treatment is done using m = 3 drugs [10]
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3.4.1 Drug Combination vs. Treatment Success
The degree of cross-resistance varies from one drug to another. For example, for three drugs com-
binations there can be five different possibilities, based on pairwise combinations of cross-resistance
properties and the triple-resistance property of drugs in use as shown in the figure 3.3. Let
N = 108 − 1013 and drug induced death rate of sensitive cells be ten times the growth rate of
cancer (d = D + H = 10L), under no treatment let D = 0 − 70% of L. Also let ki = k = 10 − 100
& k123 = 1. Observation gained from figure 3.4 implies that,
• Under no cross resistance, treatment success increases with number of drugs m.
• Two drugs with cross resistance is better than single drug for treatment in CML.
• Additional third drugs do not make significant difference to the treatment success.
• Result obtained in figure 3.4 is independent of kinetic parameter, [10][16]
.
Figure 3.3: Possible combinations of three drugs cross resistance network [10].
Figure 3.4: The probability of successful therappy vs. colony size, log10N . Parameters values are u = 10−9,
k = 100, M0 = 100, D/L = 0.5, H/L = 3. ”I”,”D”, ”N”, ”K” stands for imatinib, dasatinib, nilotinib &
future drugs to bind T315I mutant respectively [10].
24
By looking at the figure 3.5(A)) we can say that two drug combination become insignificant if
mutant resistant to one drug only is very. If mutation rate for only one drug (say k = 1000) is un-
realistically high (figure 4.5(B)) then, combining third drug may be advantageous. On a qualitative
level, treatment success is independent of parameters like death rates or growth rates etc. Refer
figure 3.6.
Figure 3.5: The probability of successful treatmet vs. colony size, log10N . (A) Here k = 10. (B) Here
k = 104 [10].
Figure 3.6: Parameter dependence on the treatment success/ failure. (A) Natural Death rate dependence:
Parameters values are D/L = 0 (solid lines) and D/L = 0.8 (dashed lines); H/L = 10. (B) Drug-induced
death rate dependence: H/L = 3 (solid lines) and H/L = 400 (dotted lines); D/L = 0. Other parameters
are same as in Figure 3.4 [10].
3.5 Conclusion and Discussion
• Combining two drugs out of imatinib, nilotinib & dasatinib is advantageous over only one.
• Results are independent of natural/drug-induced death rate of cancer cell colony[8].
• Treatment success is high iff N ≤ 1010. However the figure is higher than this at diagnosis.
• Three drug combination doesn’t improve treatment success.
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Chapter 4
Quiescence Effect vs. Drug
Resistance
4.1 Introduction
Tumor stem cell dynamics affects the emergence of resistant mutant. In this chapter we will focus
our attention on the dynamics of tumor stem cell quiescence. We will look at two new events along
from those described in death birth process in previous chapters namely, cells entering quiescence
state and cells coming out of the quiescence state or moving into active state. When cells become
inactive they are said to be in quiescence state. The result shows that when treated with single
drug, the treatment failure is independent of quiescence parameters which is not the case when two
or more drugs are used for treatment. Al the analysis carried out is in context of treatment of CML.
4.2 Model: Cellular Quiescence vs. Drug Resistance
Stochastic model comprises of Active CML cells and quiescent CML cells. Active CML cells re-
sponds to mutations and drug activity while Quiescent cells are inactive to any drug activity. Before
we move on to modeling exercise, Let us describe few parameters with the following notations,
• N : Tumor size at which cancer is detected and imatinib therapy starts.
• u : Mutation rate.
• L : Rate of division of active CML cells.
• d : Natural as well as drug induced death rate of active CML cells.
• α : Rate at which an active cell enter quiescent/inactive state.
• β : Rate at which quiescent cells enters active state.
GOAL: We will calculate the probability that all the cancer have died out as a result of applied
therapy and no resistant mutant is present or is spreading out during the cell extinction. We will
also look at the parameter dependence like cellular growth, mutations, quiescence, and death and its
relation to probability of successful therapy. We will re-use the same model as developed in chapter
2 but now we include two additional parameters α and β as defined above.
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4.2.1 The framework of Quiescence effect in CML
Under the absence of resistant mutants the system state (i, j) comprises of number of cycling cells
denoted by i and the number of quiescent cells given by j. In an infinitesimal time instent ∆t vari-
ous events that happens in the colony of active and quiescent cells can be briefly described as follows,
• Cell Division: Active cell increases, (i, j) → (i+ 1, j) with probability i L∆t;
• Cell Death: Active cell dies, (i, j) → (i− 1, j) with probability i d∆t;
• Quiescent effect: Active cell transforms to Inactive cell, (i, j) → (i− 1, j + 1) with probability
i α∆t;
• Reverse Quiescent effect: Quiescent cell turns active (i, j) → (i + 1, j − 1) with probability
j β ∆t;
• No Change: State floats, (i, j) → (i, j) with probability 1− (i[L+ d+ α] + jβ)∆t.
The events and associated probability can be formulated in a combinatorial network and can be
presented in a similar way as seen earlier in chapter 2 using Kolmogorov forward equation as,
˙ϕi,j =L(i− 1)ϕi−1 + d(i+ 1)ϕi+1 + α(i+ 1)ϕi+1,j−1
+ β(j + 1)ϕi−1,j+1 − ϕi,j
[
(L+ d+ α)i+ βj
] (4.1)
We are interested in the statistical behavior, as statistical behavior captures better insight into the
process of quiescence. The statistical namely, mean number of active & quiescent cells denoted by
(x, y) is shown below.
x =
∞∑
i,j=1
iϕi,j and y =
∞∑
i,j=1
jϕi,j (4.2)
Solving Eq.4.1 and Eq.4.2 we get,
x˙ = (L− d− α)x+ βy ; y˙ = αx− βy where x(0) = I0, y(0) = J0 (4.3)
We can extend the system to accommodate multiple drugs ”m”. We will assume symmetrical
parameters value in use namely, Ls = L, αs = α, βs = β, ds = 0. The following system is same as
equation 4.3 but considered for m number of drugs now under symmetric coefficient.
x˙0 = (L(1− u0)− α)x0 + βy0
y˙0 = αx0 − βy0
.......
x˙k = Luk−1xk−1 + (L(1− uk)− α)xk + βyk
y˙k = αxk − βyk 0 < k ≤ m
where uk = (m− k)u
(4.4)
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4.3 Statistical Results under β = 0
Let us consider that the factor β = 0 and analyze the results obtained after solving the above systems
of equation. We can obtain an analytical form of equation. Later we will see the case where rate of
cell awakening β is a non zero quantity.
4.3.1 The expected number of mutants
The expected number of mutants for any class k can be given by,
∑m
k=0(xk + yk) =
L exp[(L−α)t]−α
L−α (4.5)
If the expected number reaches size N then the time taken to reach the size is,
t∗ =
ln
[
N(L−α)+α
L
]
L− α
4.3.2 Cycling cells fraction at size N
The fraction of cycling cells [10] of class k at size N is,
xk
xk+yk
=
(
1− αL
)
(1 +O(1/ln N)) +O(u) (4.6)
4.3.3 Mean number of mutants resistant to m drug
The mean number of mutants resistant to all m drugs [10] can be written as,
xm(t∗) + ym(t∗) = N
[
u lnN
(1−αL )
]m
+ h.o.t (4.7)
Figure 4.1: Plot of statistical parameters as described in Eq.4.6 and Eq.4.7. [10]
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Lets plot Eq.4.6 and Eq.4.7 w.r.t α while neglecting higher order terms. We observe that if m
increases the dependence of total number of mutants becomes stronger, figure 3.1(b). If we use only
one drug, m = 1, then we see that the mean number of cyclic mutants of class k = 1 is given by,
xk = N u lnN (4.8)
The quantity xk is independent of α, but depends on colony size N and mutation rate u. figure 4.2.
Figure 4.2: Numerical Solution for system described in Eq.6. [10]
4.3.4 Total number of fully resistant mutant
Wm−1 = mNu
[
u lnN
(1− αL )
]m−1
For m = 1, Wm−1 is independent of α while for m > 1 the quantity depends on α.
4.4 Numerical Results: The case β > 0
If we says that the quiescent cells turns active or the value of β > 0 then, a closed form of analytical
solution cannot be obtained. However, numerical results can be obtained with the aid of graphical
representation as shown in figures below.
• The total mutant amount of class k decays with β, figure 4.3(a).
• Cycling cell fractions increases with β, figure 4.3(b).
• Cell awakening fraction β is opposite to quiescence rate α.
4.5 Parameter α and β dependence on mutant elimination
In most cases the tumor growth phase before treatment invokes resistance evolution rather than
the treatment phase, we calculate the probability of successful therapy under quiescence parameter
α and β. Several scenarios are considered in the figures below for different number of drugs used,
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Figure 4.3: System dependence on β. [10]
mutation rates and the cancer size. Figure 4.4 and 4.5 illustrates the dependence of quiescence
parameter α and β when resistant mutants vanishes completely under varying parameter values.
Figure 4.4: probability of having no fully resistant mutants at size N for different quiescence param-
eters
Figure 4.5: probability of having no fully resistant mutants at size N for different quiescence param-
eters
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Chapter 5
Drug Administration Regimens
5.1 Introduction
It has now been established that drug resistance is the central cause of failure of may cancer targeted
drugs. If such resistance is inevitable or inherent to many cancer then can we delay its emergence
once it is detected? Can we do it in an optimal fashion such that the delay of resistance emergence is
maximum? What are the drug administration regimens which can achieve our target with minimum
side effects? We will review these topics in this chapter. The drug administration strategy at present
is continuous in time meaning that drugs are administered at very low dozes on daily basis without
any drug holidays to limit the side effects but still effective on killing malignant cells in cancer.
There can be an alternative strategy where drug can be administered in a pulsed fashion meaning
that a high doze of drug pulse for a fixed number of days followed by complete rest to the person in
order to cope up the side effects of the drug. It is well understood that there is a tolerance limit of
a person to withstand the side effects of drugs. High concentration of drug can lead to large scale
killing of cancer cells but with severe side effects while low dozes of drugs cannot compensate the
rate of growth of cancer with the drug induced death rate of the cells. However, low concentration
of dugs can have little side effects on persons day-to- day life. We ask ourselves that is there any
intermediate solution between these two regimens? If it exist then, can it be administered in in
optimum sense?
Some investigation on this issue claims that low doze continuous dozing strategy is effective in
treatment [17] while some claims that high doze drug administration is fruitful [18]. Earlier a model
of kinetic resistance to cell-cycle therapy was propose by Norton and Simon [19] for chemotherapeutic
treatment. They suggested that if intensity of treatment was increased then one can combat the
slow rate of tumor regression and increase the chances of cure. The model is named after them
as Norton-Simon hypothesis [19]. In past there have also been a substantial effort to model the
genetic resistance [11]. Iwasa et.al. used a multi-type birth-death process model to study the
genetic resistance [20][21]. A model for multi-type birth-death process using multi-drug was also
seen in the work of Komarova and Wodarz [12][13]. In this chapter we will develop a stochastic
framework of a non-homogeneous multi-type birth-death process. The drug concentration profile
which is administered in a pulsed fashion over time determines the growth parameters of cancer [1].
In the end, an optimal control problem is formulated to delay the resistance emergence maximally.
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5.2 General Pulsed Administration Drug Dozing Schedule
In this section we will look at another stochastic process of evolution of sensitive and resistant cells
according to a process called as multi-type branching process [4]. The growth and death rate of
cancer is determined by the drug doses administered in a pulsed fashion whereby, high doze of drugs
administration is followed by drug holidays for recovery. During drug therapy the cell population
reduces in size due to high death rate of sensitive cell given by c1 as compared to birth rate as q1. The
corresponding rates for resistant cells are c2 and q2. During drug holidays the resistant cells emerge
with birth and death rates as r2 and d2. Also the birth and death rate of sensitive cells during drug
holidays are r1 and d1. The genetic alteration conferring resistance is due to single mutation only.
If we look at the figure 5.1 we can see that the length of pulse Ton for treatment phase is different
from drug holiday which is Toff , also assume K = Ton + Toff , αon = q1 − c1,, αoff = r1 − d1, and
γ = αonTon + αoffToff < 0. We also see that when Toff = 0 then the regimen becomes continuous
dosing scheme, which reduces to a special case of pulsed dosing scheme. From now on we will treat
continuous drug dozing strategy as the special case of general pulsed drug dosing strategy. In figure
5.1 when growth rate of sensitive cell is low (0.5 here) then the population of sensitive cell decreases
over time in pulsed dosing regimen. But, when the growth rate of sensitive cell is high (1.8 here)
then the population of sensitive cell increases over time. In the absence of treatment cell colony
evolves at a higher rate ie., r1 > d1 and r2 > d2. If r2 = d2 and d2 = c2, then drug in use is
ineffective against resistant cancer cells and confers complete resistance. It is useful to calculate
the probability of resistance and optimize the dosing schedule in such a way that this quantity is
minimum. Let us look at how we can achieve this. If complete resistance has occurred then the
probability of the absolute extinction of resistance cells starting from one is d2r2 [4] irrespective of
drug dosing schedules. To looker deeper into the process dynamics it its essential to calculate few
parameterized quantity under a certain time frame [0,T] like:
• Average number of sensitive cell at any instant of time.
• Sensitive cell division count as a result of branching in time interval [0,T].
• The number of resistant mutant produced in time interval [0,T].
• Expected count of sensitive cell birth until it gets extinct.
• The number of regimen cycle for sensitive cell extinction.
• Probability to produce one fully resistant clone before sensitive cell population extincts.
• Expected number of resistant cell at time T .
• Compute the above quantities under partial resistance and also for continuous dozing regimen.
[i] The Average number of sensitive cell at any instant of time is approximated as,
p(t) = M exp(αont) M : Number of sensitive cells.
[ii] The sensitive cell division count produced in branching process in time interval [0,T]
b(T, q1, c1,M) =
∫ T
0
Mq1 exp(αons)ds
=
[
Mq1
q1 − c1
]
exp
(
[αonT ]− 1
) (5.1)
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[iii] The resistant cell clones are produced from the sensitive cells as a result of mutation. The
number of such resistant cells in the time interval [0,T] is distributed binomially. We can write the
distribution law as,
Bin
(
b(T, q1, c1,M), u(1− d2
r2
)
)
.
[iv] The expected number of sensitive cell birth
The sensitive cells produced at the beginning of ith treatment cycle and; ith holiday is pi,0 and pi,1
respectively. The quantity is given as,
pi,0 = Mexp
(
(i− 1)γ
)
pi,1 = Mexp
(
(i− 1)γ
)
exp
(
αonTon
) (5.2)
[v] The number of total birth of sensitive cells until the cell colony gets extinct is,
We use equation 5.1 and 5.2 under the binomial distribution law to arrive at the following equation.
B = 1−exp(Wγ)1−exp(γ)
[
q1
q1−c1 exp
(
αonTon − 1
)
+ r1r1−d1 exp
(
αoffToff − 1
)
exp
(
αonTon
)]
(5.3)
Figure 5.1: The growth dynamics of sensitive cancer cells during various treatment regimens.
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[vi] Total number of cycles W needed for sensitive cell population to extinct
W ≈ 12
[
loge
1
M
]
γ−1 (5.4)
[vii] Probability to produce one fully resistant clone before sensitive cells extinct.
The surviving resistant cell count produced from the sensitive cell clones is binomial distributed as,
Bin
(
B, u(1− d2
r2
)
)
.
The Poisson approximation of the above binomial distribution is done and the probability to produce
one fully resistant clone obtained is,
P = 1− exp
[
−Bu(1− d2r2 )
]
(5.5)
[viii] The expected number of resistant cells at time t = T .
If a resistance clone is produced then it keeps on replicating identical resistant cell clones. To
estimate the number of such cells at any given time t = T we need to estimate the production of
resistant cell in any given small time interval and then estimate its growth till time t = T . We need
convolution operator to achieve this.
R(T ) = u
∫ T
0
B
′
(t)exp
[
(T − t)(r2 − d2)
]
dt
∼= Muγ − exp(T (r2 − d2)) + exp(Tγ/(Ton + Toff ))[
(exp(γ)− 1)(d2 − r2)(Ton + Toff ) + γ
] (5.6)
5.3 Continuous Dosing Regimen as a special case
Of we just include Toff = 0 in the analysis that we did in previous section we can obtain all the
parameters for continuous dosing regimen. Thus, continuous dozing regimen becomes a special case
of general pulsed dosing regimen. The quantities obtained from previous analysis under Toff = 0
can be given as,
B ∼= (1−M)q1(q1−c1) (5.7)
P = 1− exp
[
−Bu(1− c2q2 )
]
(5.8)
R(T ) = Muq1
exp[(q1−c1)T ]−exp[(r2−d2)T ]
(q1−c1)−(r2−d2) (5.9)
5.4 The case when resistance exist prior to treatment
It is generally seen that there exist a small amount of resistant cells before therapy begins. This
result is also presented in previous chapters. So what do we need to do in our existing result in
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order to accommodate the change made in assumption of pre-existance of resistant mutants? We
can intelligently classify the population of size M into two classes such that the first class comprises
of M(1− s) sensitive cells and the other class comprises of Ms resistant cells. In order to avoid the
emergence of resistance the following conditions should satisfy,
• Resistant mutant which exist prior to treatment should get extinct and,
• No more resistant clone are produced from sensitive cell division during treatment.
The probability associated with avoiding resistance is nothing but the product of these two proba-
bilistic event. The probability to avoid resistance is,
P er = 1− (q2/c2)Ms if q2 < c2
P er = 1 otherwise.
(5.10)
In a similar analogy the expected number of resistant cell population at time t = T under pre-existing
mutant is,
R(T ) ≡ Rs(T ) +Ms exp[(q2 − c2)T ] (5.11)
Figure 5.2: The Probability of resistance and expected number of resistant cells during continuous dosing scheme.
(A) Parameters: M = 10000, q2 = 1.25, u = 10−5, and c1 = c2 = 1.0 (B) Parameters: q1 = 0.75 and others as (A).
(C) Parameters: M = 1000, q2 = 1.2, u = 10−4, and others as (A). (D) Parameters: q1 = 0.5 and others as (C). [1]
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5.5 Analytical Results vs. Numerical Simulation [1]
5.5.1 Continuous Administration Strategies
Let us first look at the numerical computation and parameter dependence on the probability of
resistance under continuous dosing scheme which is nothing but a special case of general pulsed
dosing scheme. It can be seen from figure 5.2(A) that as the rate of growth of sensitive cell population
increases the chances of resistance formation accelerates. In figure 5.2(B) the relation is linear for the
initial sensitive cell colony size M vs. the probability of resistance. There is a constant upward drift
in the expected number of resistance cells w.r.t time under increasing growth rate q1 of sensitive cell
colony in figure 5.2(C) whereas, in figure 5.2(D) the expected number of resistant cell as a function
of time is much more sensitive to the increase in the growth rate q2 of resistance cell population.
Figure 5.3: The probability of resistance and expected number of resistant cells during
pulsed therapy. Parameters: M = 1000, r1 = 1.3, r2 = q2 = 1.1, u = 10
−4, d1 = d2 = c1 = c2 =
1.0, and q1 = 0.5 [1]
5.5.2 Pulsed Administration Strategies
The numerical computation and parameter dependence on the probability of resistance under pulsed
dosing scheme is shown in the figure 5.3. It can be seen from figure 5.3(A) that as the rate of growth
of sensitive cell population increases the chances of resistance formation accelerates where in figure
5.2(B) the relation is opposite when growth rate of resistant cell population is taken into account.
In figure 5.3(D) the relation is linear for the initial sensitive cell colony size M vs. the probability of
resistance whereas, the probability of resistance decreases exponentially w.r.t the drug dosing period
Ton as seen in figure 5.3(C). There is a constant upward drift in the expected number of resistance
cells w.r.t time under increasing growth rate q1 of sensitive cell colony in figure 5.3(E) and in figure
5.3(F) the expected number of resistant cell as a function of time is much more sensitive to the
increase in the growth rate q2 of resistance cell population.
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5.6 Optimizing dosing strategies
Finally we have reached to the end of our topic where we will discuss about the optimization of
various treatment regimens in order to minimize the probability of generating resistance or delaying
it to maximum extend in worst case. In an optimal control problem there are certain constrains. In
our case we will have toxicity constrains determined through experimental data for each drug types.
If we change the treatment schedules then the parameters which gets affected are as follows,
• On / Off treatment pulse duration, Ton / Toff ,
• Dose intensity affects the rate of growth q1 and the rate of death c1 of sensitive cell.
• Growth rate r1 and death rate d1 of the resistant cells are unaltered under complete resistance,
• All other parameter remains unaffected.
The quantity Ton and Toff are related as K = Ton + Toff while q1 and c1 are drug concentration
dependent parameter. So, toxicity constraints can be a function of two parameters only, We can
see an example toxicity constraint (obtained through experiments) in figure 5.4(A). It defines the
maximum tolerated time duration of treatment Ton, based on the death rate of sensitive cancer cells,
for a 28-day treatment cycle [1]. Other such constraints family curve are shown in figure 5.4(B) and
5.4(C). We can use as many toxicity constraints families in order to test the probability of resistance.
Figure 5.4: Toxicity constraint curves needed for optimization [1]
One such curve as an example is shown in figure 5.5. We can adjust the parameter in order to fall
within the constraint limits and design the optimal drug dosing schedules. Consider the following
flexible constraint of three constraints families as shown in the figure 5.5.
Figure 5.5: Toxicity constraint curves needed for optimization [1]
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• Family [1] Vary maximum dose that can be tolerated for K(=28) days,
• Family [2] Vary maximum dose that can be tolerated for just one day,
• Family [3] Vary initial rate of decrease in Ton by increasing concentration.
The three constraints family curve is denoted by T 11 , T
i
2 and T
i
3. In the notation, T
i
j , j denotes the
constraint family (1st, 2nd and 3rd) and the superscript i specifies the function they perform in the
family. The function defining the first toxicity constraints family as shown in figure 5.5(A) is,
T i1(c1) =
(6−Bi)2
(c1 −Bi)2
Bi =
ai
√
K − 6√
K − 1
(5.12)
The variable parameter for this family is is ai. We set the value for the variable parameters as
a1 = 2.1, a2 = 2.3, a3 = 2.5 to obtain the three curves in each family as can be seen in the figure for
each family. Similarly second family toxicity curve is shown in figure 5.5(B).
T i2(c1) =
(bi −Bi)2
(c1 −Bi)2
Bi =
2.3
√
K − bi√
K − 1
(5.13)
The variable parameter for second family is bi and the value that is set for three curves within the
family is b1 = 5, b2 = 6, b3 = 7. After the toxicity constrained has been established we find the
area under the toxicity curve in order to minimize the probability of resistance. The optimal point
should lie within this area. Let us focus our attention on the first toxicity constraint family. The
rest follows the same procedure of optimization. Consider the curve with the following parameters
i = 1,K = 28, a1 = 2.1,M = 10
9, u = 5.1−10, r2 = r1, d2 = d1. For this curve
B1 =
2.1
√
28− 6√
28− 1 = 1.1912
T 11 (c1) =
(6− 1.1912)2
(c1 − 1.1912)2
Minimize
ci
c1T
1
1 (c1)
=⇒ c1 = 3.15
If we put the value in figure 5.5(A) we get the corresponding Ton value as 6.05 days. Now we can
obtain other optimal values once we get Ton. Now, Toff = K − Ton = 21.95 days. We can calculate
all other parameters values using c1 = 3.15. That conclude our optimal drug dosing regimen.
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